Drugs / JNJ-89862175
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07223125 | Oct 2025 → Dec 2026 expected | high grade malignant neoplasm | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-89862175 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07223125 ↗ |